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Objective: Compare CT perfusion between responders and non-responders in patients with
residual cervical nodes after lymphoma treatment.
Subjects and methods: Twenty-seven patients with treated pathologically proved lym-
phoma were included in this prospective study, divided into two groups: responders (n.
15) and non-responders to treatment (n. 12). Blood flow (BF), blood volume (BV), mean
transit time (MTT) and permeability (PS) were determined using CT perfusion. Lymph
nodes sizes were measured (short axis).
Results: BF, BV and PS were significantly higher in non-responders group [93.3 (65.3–111)
ml/min/100 g, 6.3 (5.2–8) ml/100 g and 18.9 (14.5–25.1) ml/min/100 g respectively] as
compared to responders group [54 (43.8–77.5) ml/min/100 g, 4.1 (2.2–4.8) ml/100 g and
9.4 (7.5–14.5) ml/min/100 g respectively], [p 0.019, 0.004 and 0.004 respectively]. MTT
had a trend to be low in non-responders group, but did not reach statistical significance
(p 0.305). Cutoff value for BF, BV and PS was 59.5 ml/min/100 g, 3.6 ml/100 g and
11.1 ml/min/100 g respectively, 92% sensitivity for the three parameters and specificity
67%, 47% and 73% respectively. Lymph node sizes had no relation to the perfusion param-
eter values.
Conclusion: CT perfusion is a functional imaging tool with promising results in differenti-
ating between responders and non-responders in treated lymphoma patients, using BF, BV
and PS.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Computed tomography (CT) is still the most commonly
used imaging tool for initial staging and follow up of lym-
phoma. However, CT has low accuracy in the diagnosis of
relapse, identification of viable tumor masses is usually
not possible by CT. The presence of residual mass after
treatment occurs in 64–88% of cases in both lymphomasubtypes [1–5]. A functional imaging tool to monitor the
activity of any residual tissue is favored in lymphoma [4–6].
Fluorodeoxyglucose positron emission tomography
(F-FDG PET) has advanced to a state-of-the-art imaging
technique in staging and monitoring the response to treat-
ment of lymphoma, due to its high sensitivity for assess-
ment of tumor vitality [7–9]. The main disadvantage of
F-FDG PET is its high false positive results caused by reac-
tive tracer uptake, e.g. thymus hyperplasia, sarcoidosis or
inflammation [5,6,10–12].
Non-invasive measurements of tumor related angio-
genesis represent an alternative approach to the
characterization of residual lymphoma masses. Vascular
characteristics, such as vessel wall permeability and
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combined with the routine conventional CT [5,6,12].
CT perfusion is suitable for this purpose due to its wide-
spread availability, plus that CT is already used for lym-
phoma staging and follow up of all patients. A key
advantage of CT perfusion is the linear relation between
iodine concentration and tissue density changes which
means direct calculations in a more simple way than Mag-
netic resonance imaging (MRI). In addition, the routine
availability of commercial software for CT perfusion for
tumor diagnosis [13].
The data on the usefulness of CT perfusion in lymphoma
patients are limited [4,13]. The chief reason for this is the
idea that angiogenesis is not a predominant feature of lym-
phoma as compared to other types of malignancies [13].
However, results of previous studies demonstrated that
active lymphoma revealed an increase in perfusion values
as compared to inactive lymphoma [12]. Moreover, the
degree of residual lymphoma perfusion at end of treatment
helps to identify patients likely to remain in remission
1 year after completion of therapy [5].
The aim of this study was to evaluate the role of CT
perfusion in the differentiation between responders and
non-responders after treatment of lymphoma patients.2. Materials and methods
Institutional review board (IRB) approval was obtained
for this prospective study.
2.1. Subjects
Our study included 27 patients (12 males, 15 females),
their ages ranged between 18 and 70 years with median
age 47 years. General inclusion criteria were; pathologi-
cally proved lymphoma, treated for more than 3 months
or after finishing at least one cycle of chemotherapy, follow
up post contrast CT showed residual cervical lymph nodes
more than 1 cm in its short axis (fine needle aspiration
cytology FNAC revealed 19 cases of NHL, 14 of them were
diffuse large B cell type Diffuse large B cell lymphoma
(DLBCL), and 8 cases of Hodgkin lymphoma (HL)).
Patients were divided into two groups; group 1, respon-
ders to treatment (partial remission PR or stable disease
SD) and group 2, progressive disease PD. Inclusion criteria
for group 1 were; final clinical assessment suggests PR or
SD, and comparison with previous pretreatment CT
showed same or decrease in cervical nodal size. Inclusion
criteria for group 2 were; final clinical assessment suggests
PD, and comparison with previous pretreatment CT
showed increase in cervical nodal size. Exclusion criteria
were general contraindications of post contrast CT; Preg-
nancy, hyperthyroidism, renal impairment (creatinine
level >1.5), history of hypersensitivity for iodinated con-
trast media, heart failure.
2.2. CT perfusion technique
Dynamic CT acquisitions were performed on a 64-MDCT
scanner (Brilliance 64 CT scanner, Philips Healthcare, BestNetherlands). First, a non-contrast CT scan was performed
which served as a localizer to determine the desired
scanned region to be included in the dynamic study. Low
tube peak kilovoltage and low tube current were used for
the localizer scan (80 kVp and 150 mAs) as well as slice
thickness (5 mm).
The dynamic study consisted of eight contiguous slices,
of 5 mm thickness each. The dynamic acquisition was per-
formed using low tube voltage 80 kVp and tube current
200 mAs. The scan duration was 50 s to cover the first pass
of contrast and allow for calculation of permeability sur-
face area product as well. The temporal resolution was
one image per two seconds, with total 25 images for each
of the eight slices. Imaging was initiated 6 s after the injec-
tion of contrast. The total dose of contrast was 50 ml of
non-ionic iodinated contrast agent (Optiray 350 mg/ml
Mallinckrodt Medical, Pmc, Mallinckrodt, Inc.). The rate
of injection was 5 ml/s. This was followed by 20 ml saline
flush with the same rate of injection to keep the injection
bolus tight and prevent its retention in venous line. An
automated power injector and a 16-G antecubital cannula
were used. Patients were instructed to breathe quietly and
to avoid deglutition.
Temporal resolution of one image per two seconds was
used to lower the radiation dose in all patients [14].
2.3. Post processing
For all cases post-processing was done using separate
workstation (Advantage Windows 4.2; GE Medical Sys-
tems, Mi.) running the perfusion software (Body perfusion
3 Perfusion 3; GE Medical Systems). All the dynamic CT
images were reviewed in the cine-mode to insure the
absence of significant motion artifacts.
An arterial input ROI was manually inserted using a
standardized circular ROI. The resultant arterial time
attenuation curve was reviewed to insure the presence of
a rapid rise to a high peak, followed by rapid descent of
attenuation. Identification of the start and the end of first
pass of contrast was then done manually.
The software automatically generates the following
perfusion parametric maps: BF (ml/min/100 g), BV
(ml/100 g), MTT (seconds), and PS (ml/min/100 g). Every
pixel of the images obtained is attributed a color which
represents a numeric value of the perfusion parameter cal-
culated for that pixel.
The dynamic CT section showing maximum nodal
diameter was selected from the available 8 sections and
a free-hand ROI was traced around tumor boundaries to
encompass as much nodal tissue as possible avoiding large
vessels, areas of necrosis and peri-nodal tissue. The soft-
ware calculated numeric values for each ROI which corre-
sponds to the average BF, BV, MTT and PS in this ROI. The
perfusion values for the lymph node were recorded for
every patient.
2.4. Statistical analysis
Test of normality was done to the data, which was
found to be non-parametric. Statistics were done using
SPSS 16, and the median (interquartile range) of the four
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the two groups was calculated. The results were compared
using mann-whitney test, p values less than 0.05 were con-
sidered significant.
When statistical significance was found, ROC curve
analysis was performed to define cut off values between
the two groups.
Pearson’s correlation coefficient was used to test for
correlation between the lymph node size and different per-
fusion parameters.3. Results
Responders group (1) were 15 patients (9 males and 6
females), and non-responders group (2) were 12 patients
(3 males and 9 females).
No significant difference was noted between both
groups as regarding the mean age and gender, as shown
in Table 1, both p-values were non-significant.
Median, interquartile range and results of comparison
between BF, BV, MTT and PS are summarized in Table 2,
Fig. 1. There was significant difference between the BF,
BV and PS of the responders group and the non-
responders group (Figs. 3 and 4), p-value was (0.019,
0.004, and 0.004 respectively). On the other hand, there
was no significant difference between MTT of both groups
(p-value was 0.305).
The receiver operating characteristic curve (ROC curve)
was done for the three significant parameters. ROC curve
analysis results for BF, BV and PS are demonstrated in
Table 3. Results revealed a cutoff value for BF, BV and PS
(59.5 ml/min/100 g, 3.6 ml/100 g and 11.1 ml/min/100 g
respectively) (Fig. 2).
When testing for correlation between the size of the
selected lymph node of all cases and different perfusion
parameters, there was no significant correlation (all
p-values were >0.05).
The radiation dose recorded with our CT perfusion
technique was (computed tomography dose index
CTDI vol = 46.9 mGy and dose length product DLP =
187.6 mGycm).Table 1
Age and gender comparison between group 1 and group 2.
Group 1 (responders to treatme
No. of patients 15
Mean of age ± SD 45.47 ± 17.89
Gender 9 males, 6 females
Table 2
Perfusion parameters of responders to treatment (partial remission PR or stable
Relapsed disease.
Parameter Responders med
(interquartile ran
Blood flow (ml/min/100 g) 54 (43.8–77.5)
Blood volume (ml/100 g) 4.1 (2.2–4.8)
Mean transit time (s) 6.9 (4.6–8.8)
Permeability surface area product (ml/min/100 g) 9.4 (7.5–14.5)
* p-Value is considered significant if <0.05.4. Discussion
In our study, we discovered significant difference
between the values of BF, BV and PS between responders
and non-responders to treatment groups, using CT perfu-
sion parameters quantitative values.
CT perfusion is a unique CT technology that enables
functional imaging by both qualitative and quantitative
assessment of tissue vasculature [15].
The data on the role of CT perfusion in lymphoma
patients are limited [4,13]. The chief reason for this is the
idea that angiogenesis is not a predominant feature of lym-
phoma as compared to other types of malignancies [13].
In this study, blood flow (BF) was significantly higher in
non responders than in responders, and this can be used in
the differentiation between responders and non-
responders to treatment (p-value 0.019). That was in
agreement with Dugdale et al. [4], who investigated 39
patients with proved lymphoma in their study, the median
perfusion values were higher in active disease than in non-
active disease (0.55 vs. 0.37 ml/min/100 g). Our results
were also in agreement with Syha et al. [5] who compared
perfusion parameters before and after treatment in 26
patients, and found significant reduction of BF in lym-
phoma patients at end of treatment (P < 0.001).
In our work, blood volume (BV) and permeability (PS)
were significantly higher in non-responders than in
responders, and this can be used in the differentiation
between responders and non-responders to treatment
(same p-value 0.004 for both). There was a trend for MTT
to be lower in non-responders than in responders to treat-
ment, but did not reach statistical significance. Miles & Kel-
ley [16] were not in agreement with our study, they found
no difference between treated and untreated patients in
mean value of BV. Our results were in agreement with Syha
et al. [5], who found significant reduction of BV in lym-
phoma patients at end of treatment (P < 0.001). Syha
et al’s [5] results match the hypothesis that assumes that
the vascularity of lymphoma decreases after successful
treatment. Miles & Kelley [16] were not in agreement with
our study, they found no difference between treated andnt) Group 2 (non-responders to treatment)
12
48.17 ± 13.53
3 males, 9 females
disease SD) and non-responders to treatment: Progressive disease PD/or
ian
ge)
Non-responders median
(interquartile range)
Significance p-value*
93.3 (65.3–111) 0.019*
6.3 (5.2–8) 0.004*
5.3 (4.4–7.3) 0.305
18.9 (14.5–25.1) 0.004*
Fig. 1. Box plots for CT perfusion parameters, in responders and non-responders groups, obtained from cervical lymph nodes in lymphoma patients (A) BF
median value is higher in non-responders than in responders, and reached statistical significance. (B) BV median value is higher in non-responders than in
responders, and reached statistical significance. (C) MTT median value is lower in non-responders than in responders, and reached statistical significance.
(D) PS median value is higher in non-responders than in responders, but not statistically significant.
Table 3
Diagnostic accuracy of BF, BV and PS in evaluation of the response to treatment.
Parameter Area under curve (AUC) Cutoff value Sensitivity Specificity p-Value
BF 0.767 59.5 ml/min/100 g 0.92 0.67 0.019
BV 0.828 3.6 ml/100 g 0.92 0.47 0.004
PS 0.828 11.1 ml/min/100 g 0.92 0.73 0.004
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Also Dugdale et al. [4], found that median values of perme-
ability were slightly different between active and inactive
disease. Syha et al. [5] were in agreement with our work,
they found that reduction in k-trans was significant for
patients who underwent VPCT at both baseline and end
of treatment.
The cutoff value proposed by our results for BF was
(59.5 ml/min/100 g, sensitivity was 91% and specificity
was 66%). That was not in agreement with Dugdale et al.
[4], who found that Perfusion below 0.2 ml/min/100 g
means inactive disease (p < 0.03), which is much lowerthan our cutoff value. Their use of an indirect semi-
quantitative method to calculate the perfusion parameters
might be the cause. Our work was also not in agreement
with Syha et al. [5] did CT perfusion at end of treatment
of lymphoma, BF > 18.51 ml/min/100 g meant they are
non-responders (sensitivity 92.86%, specificity 72.73%,
accuracy 84%). The cause of such disagreement might be
that our high grade lymphoma cases are more than those
in Syha et al’s [5] study. Cutoff values for BV & PS were
3.6 ml/100 g and 11.1 ml/min/100 g respectively, with
92% sensitivity for the two parameters and specificity
47% and 73% respectively.
Fig. 2. Receiver operating characteristic (ROC) curves for blood flow (BF), blood volume (BV) and permeability (PS), as a test for differentiation between
responders and non-responders to treatment in lymphoma patients. The curve shows high diagnostic performance and is higher and shifted to the left
denoting the highest sensitivity and specificity.
Fig. 3. A 55 years old female patient, treated case of NHL, responder to treatment: (A) blood flow color map shows low perfusion, it equals 55.7 ml/min/
100 g, (B) blood volume color map shows low blood volume, 3.1 ml/100 g, (C) MTT is high, 7.5 s, although its color map is non-representative, (D)
permeability surface area product color map shows relative high permeability, 16.9 ml/min/100 g, Permeability here is the only parameter that mismatches
with the state of the case as a responder to treatment.
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of the selected lymph node of all cases and the different
perfusion parameters, there was no significant correlation(all p-values were >0.05). This proved that the vascularity
inside the lymph node had no relation to its size, which
contradicts the assumed hypothesis, that correlate the size
Fig. 4. A 34 years old female patient, treated case of HL, non-responder to treatment: (A) blood flow color map shows perfusion higher than the surrounding
muscles, it equals 114.6 ml/min/100 g, (B) blood volume color map shows high blood volume, 8.1 ml/100 g, (C) mean transit time color map shows low
MTT, 6.2 s, (D) permeability surface area product color map shows high permeability, 11.8 ml/min/100 g. In this case, we noticed that the perfusion, blood
volume are high despite the small size of the lymph node. This emphasizes the state of the case as a non-responder to treatment.
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better assessment of recurrence.
One of the limitations of the routine use of CT perfusion
is the exposure to relatively higher radiation dose than the
conventional CT. Increasing the sampling interval to two
seconds (instead of the routinely used 1 s in most of CT
perfusion studies for head and neck tumors), the radiation
dose was nearly half the common radiation dose in CT per-
fusion studies for head and neck tumors [14]. We tried to
decrease the radiation dose in our study by using the same
technique with low radiation (CTDI vol = 46.9 mGy and
dose length product DLP = 187.6 mGycm).
Limitations of the study were; small sample size, differ-
ent pathological types of NHL and HL in an unequal distri-
bution (most of the patient were DLBCL), which eliminated
the possibility of using the pathology results in statistics.
Also we had no gold standard to measure the vascularity
in the pathology results, as mean vascular density (MVD),
to be compared with CT perfusion parameters. MVD
requires tissue excision and special pathological work,
which was not part of our protocol. Lymphoma is consid-
ered a systemic disease that affects different body parts,not only the neck. Our work on CT neck only is considered
a limitation of the study, but our aim was testing the abil-
ity of CT perfusion to detect the activity of lymphoma in a
residual lesion, which can be applied on any residual
tumor mass in other body parts in the future studies.
5. Conclusion
CT perfusion could be useful in the assessment of resid-
ual or recurrent lymphoma masses by measuring the vas-
cularity inside the mass which reflects its activity. BF, BV
and PS were the useful perfusion parameters for this differ-
entiation, we defined a cutoff value for all of the three sig-
nificant parameters (59.5 ml/min/100 g, 3.6 ml/100 g and
11.1 ml/min/100 g respectively) above which the patient
is considered a non-responder to treatment. We recom-
mend future studies with larger number of patients, for
further proof of our results.
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